Tumor necrosis factor-α (TNFα) was cloned over 2 decades ago and its identification in part
led to the discovery of a super family of tumor necrosis factors (TNFs) and their receptors …

Inflammatory bowel disease (IBD), as a representative inflammatory disease, currently has
multiple effective treatment options available and new therapeutic strategies are being …

Background Infliximab, a chimeric monoclonal antibody directed against tumor necrosis
factor α, is an established treatment for Crohn's disease but not ulcerative colitis. Methods …

Background Studies in animals and an open-label trial have suggested a role for antibodies
to tumor necrosis factor α, specifically chimeric monoclonal antibody cA2, in the treatment of …

TNF was originally described as a circulating factor that can cause necrosis of tumours, but
has since been identified as a key regulator of the inflammatory response. This review …

The gastrointestinal epithelium forms the boundary between the body and external
environment. It effectively provides a selective permeable barrier that limits the permeation …

Epithelial tight junctions (TJs) are the key structures regulating paracellular trafficking of
macromolecules. The TJ is multi-protein complex that forms a selective permeable seal …

Inflammatory bowel disease (IBD) is a chronic inflammatory state of the gastrointestinal tract
and can be classified into 2 main clinical phenomena: Crohn's disease (CD) and ulcerative …

Background & Aims: Tumor necrosis factor blockade has been shown to be an effective
treatment strategy in Crohn's disease (CD). Adalimumab is a human immunoglobulin G1 …

Objective The aim of this study was to assess the efficacy and safety of adalimumab (ADA), a
recombinant human monoclonal antibody against tumour necrosis factor α (TNF), for the …